Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 83,857 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

NCT02273596
View directory record Official record
Conditions
Wilson Disease
Interventions
ALXN1840
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Not applicable Interventional

Process and Outcomes in CBT for Anxious and Depressed Youth

NCT03100279
View directory record Official record
Conditions
Anxiety Disorders, Depression
Interventions
Coping Cat/CAT Project, Primary and Secondary Coping Enhancement Therapy
Behavioral
Lead sponsor
Rutgers University
Other
Eligibility
7 Years to 17 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 25, 2026, 9:12 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers

NCT05191862
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Cilostazol 100 mg, PMR 135 mg
Drug
Lead sponsor
Genovate Biotechnology Co., Ltd.,
Industry
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

NCT02273362
View directory record Official record
Conditions
Cirrhosis, Hepatocellular Carcinoma
Interventions
Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
6
States / cities
Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 25, 2026, 9:12 PM EDT
Not listed Phase 1Phase 2 Interventional

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

NCT04640246
View directory record Official record
Conditions
Cancer, Tumor, Solid, Refractory Cancer
Interventions
TBX-3400
Biological
Lead sponsor
Taiga Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 25, 2026, 9:12 PM EDT
Terminated Phase 2 Interventional Results available

Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

NCT03693846
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 3 Interventional

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

NCT01691846
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
aleglitazar+metformin, placebo+metformin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Maternal Mental Health in the Hospital Setting

NCT03777046
View directory record Official record
Conditions
Post Partum Depression
Interventions
Standard of Care (SOC), SOC with Psychology Therapy (CBT)
Behavioral
Lead sponsor
Michelle Lopez
Other
Eligibility
18 Years and older · Female only
Enrollment
545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Not applicable Interventional Results available

A Study of the Feasibility of Prehospital Remote Ischemic Conditioning

NCT03400579
View directory record Official record
Conditions
Chest Pain
Interventions
autoRIC® device
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 25, 2026, 9:12 PM EDT
Recruiting Not applicable Interventional

Lumbosacral Spinal Stenosis - Non-Invasive Postural Therapy for Older Adult Veterans

NCT06089746
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
NIPT
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 9:12 PM EDT
Recruiting Phase 2 Interventional

Transcranial Direct Current Stimulation for Post-stroke Fatigue

NCT05816603
View directory record Official record
Conditions
Fatigue, Stroke Rehabilitaion
Interventions
Real Soterix Mini-CT tDCS stimulator, Sham Soterix Mini-CT tDCS stimulator
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Balance: A Pragmatic Trial of a Digital Health Intervention to Prevent Weight Gain in Primary Care

NCT03003403
View directory record Official record
Conditions
Obesity, Overweight, Overnutrition, Nutrition Disorders, Signs and Symptoms
Interventions
Intervention Program
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
443 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Developing Biomarkers for Fibromyalgia

NCT00932061
View directory record Official record
Conditions
Fibromyalgia
Interventions
Traditional Acupuncture, Sham Treatment
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 25, 2026, 9:12 PM EDT
Recruiting No phase listed Observational

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

NCT06138561
View directory record Official record
Conditions
Bladder Cancer, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma, Urothelial Carcinoma
Interventions
Geriatric-8 Survey, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18), Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 25, 2026, 9:12 PM EDT
Active, not recruiting Not applicable Interventional

Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial

NCT01260961
View directory record Official record
Conditions
Autism
Interventions
Placebo, Docosahexanoic Acid
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
5 Years to 17 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 25, 2026, 9:12 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

NCT05644561
View directory record Official record
Conditions
Generalized Myasthenia Gravis, gMG
Interventions
Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 25, 2026, 9:12 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Influence of SRP With MM on the Composition and Functional Characteristics of Subgingival Microbiome Communities

NCT05422742
View directory record Official record
Conditions
Periodontitis
Interventions
SRP + MM, Scaling and Root Planing (SRP)
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 25, 2026, 9:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

NCT04923542
View directory record Official record
Conditions
Brain Metastases, HR+ Metastatic Breast Cancer
Interventions
Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 9:12 PM EDT
Recruiting Not applicable Interventional

AFO Prescription to Optimize Post-Stroke Function

NCT06692686
View directory record Official record
Conditions
Ankle Foot Orthosis (AFO), Stroke Patients, Post-Stroke Hemiparesis
Interventions
Pre-fabricated (PF) ankle-foot orthosis (AFO), Carbon-strut (CS) ankle-foot orthosis (AFO), Multifunctional articulating (MA) ankle-foot orthosis (AFO)
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Downey, California • Jacksonville, Florida • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 25, 2026, 9:12 PM EDT
Withdrawn Phase 2 Interventional

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

NCT05815186
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Interventions
Sotorasib, Ladarixin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Garden City, New York • Mineola, New York • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 25, 2026, 9:12 PM EDT
Enrolling by invitation No phase listed Observational

A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

NCT05718570
View directory record Official record
Conditions
Adult Growth Hormone Deficiency
Interventions
Somapacitan
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 25, 2026, 9:12 PM EDT
Not listed Not applicable Interventional

Quetiapine for the Treatment of Insomnia in Alzheimer's Disease

NCT00232570
View directory record Official record
Conditions
Alzheimer's Disease, Insomnia
Interventions
quetiapine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
55 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 5, 2009 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Not applicable Interventional

Helping College Students With ADHD Lead Healthier Lifestyles

NCT02829970
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Alcohol-Related Disorders, Substance-Related Disorders
Interventions
SUCCEEDS Program, Living a Healthy College Lifestyle
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years to 24 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

NCT00217373
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine, Recombinant Interferon Alfa-2b, Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine, Sargramostim
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 25, 2026, 9:12 PM EDT